Citi raised the firm’s price target on Health Catalyst (HCAT) to $10.50 from $9 and keeps a Buy rating on the shares. The analyst updated health technology models post the Q3 reports.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst Reports Q3 Revenue Growth Amid Reduced Losses
- Health Catalyst announces partnership with CyncHealth
- Health Catalyst to acquire Intraprise Health, terms not disclosed
- Health Catalyst Announces Acquisition and Leadership Changes
- Health Catalyst sees Q4 revenue 78M-$84M, consensus $80.69M